What is the appropriate long‑acting injectable (LAI) dose of paliperidone palmitate (Invega) for a patient currently on 9 mg oral Invega?

Appropriate LAI Dosing for Invega 9mg Oral

For a patient stabilized on oral Invega (paliperidone) 9mg daily, initiate paliperidone palmitate LAI (Invega Sustenna) at 150 mg equivalent on Day 1 in the deltoid muscle, followed by 100 mg equivalent on Day 8 in the deltoid muscle, then transition to monthly maintenance dosing of 75 mg equivalent (the recommended standard dose). 1, 2

Initiation Regimen

Day 1 and Day 8 Loading Doses

• Administer 150 mg equivalent (234 mg) paliperidone palmitate on Day 1 via deltoid injection 1, 2
• Follow with 100 mg equivalent (156 mg) on Day 8 via deltoid injection 1, 2
• No oral supplementation is required during the transition period, as this loading regimen achieves therapeutic plasma levels rapidly 1, 3

Injection Site and Needle Selection

• Both initiation doses must be given in the deltoid muscle to ensure optimal absorption kinetics 1, 2
• Use a 1-inch 23-gauge needle if the patient weighs <90 kg 1, 2
• Use a 1.5-inch 22-gauge needle if the patient weighs ≥90 kg 1, 2

Timing Flexibility

• The Day 8 dose may be administered ±2 days (Days 6–10) without clinically significant impact on plasma concentrations 1, 2

Monthly Maintenance Dosing

Standard Maintenance Dose

• Begin monthly maintenance injections starting 4 weeks after the Day 8 dose 1, 2
• The recommended maintenance dose is 75 mg equivalent (117 mg) administered monthly 1, 2
• Maintenance doses range from 25–150 mg equivalent (39–234 mg), adjusted based on tolerability and efficacy 1, 2

Injection Site Options for Maintenance

• Maintenance doses may be administered in either the deltoid or gluteal muscle 1, 2
• For deltoid injections, use weight-adjusted needle sizing (1-inch for <90 kg, 1.5-inch for ≥90 kg) 1, 2
• For gluteal injections, always use a 1.5-inch 22-gauge needle 1, 2

Timing Flexibility for Maintenance

• Monthly maintenance doses may be given ±7 days from the scheduled date without clinically significant impact on steady-state concentrations 1, 2

Rationale for This Conversion

Pharmacokinetic Equivalence

• The standard initiation regimen (150 mg Day 1,100 mg Day 8) followed by 75 mg monthly maintenance produces paliperidone exposures similar to oral paliperidone extended-release tablets at corresponding daily doses 4, 2
• Plasma concentrations gradually rise to reach maximum levels at a median of 30–33 days, with sustained therapeutic levels maintained over the 3-month dosing interval 4

No Direct Milligram-to-Milligram Conversion

• There is no validated direct conversion from oral paliperidone 9mg to a specific LAI maintenance dose; the standard initiation protocol applies regardless of prior oral dose 1, 2
• The 75 mg equivalent monthly maintenance dose is the recommended starting point for most patients, with subsequent adjustments based on clinical response 1, 2

Discontinuation of Oral Invega

• Discontinue oral paliperidone the day before initiating the first LAI injection 1, 2
• No tapering or washout period is required when transitioning from oral to LAI formulation 1, 2

Special Populations and Dose Adjustments

Renal Impairment

• In patients with mild renal impairment (creatinine clearance 50–80 mL/min), adjust the initiation regimen to 100 mg on Day 1 and 75 mg on Day 8, with monthly maintenance doses of 50 mg 1, 2
• Paliperidone palmitate is not recommended in patients with creatinine clearance <50 mL/min 1, 2

Hepatic Impairment

• No dose adjustment is required for mild or moderate hepatic impairment 1, 2
• No data exist for severe hepatic impairment 1, 2

Elderly Patients

• Elderly patients with normal renal function receive the same dosage as younger adults 1, 2
• If age-related decline in creatinine clearance is present, adjust dosing according to renal function 1, 2

Common Pitfalls to Avoid

• Do not attempt a direct milligram-to-milligram conversion from the 9mg oral dose to an LAI maintenance dose 1, 2
• Do not skip the deltoid loading doses on Days 1 and 8; gluteal administration during initiation results in suboptimal early plasma levels 1, 2
• Do not continue oral supplementation after initiating LAI, as the loading regimen is designed to achieve therapeutic levels without oral overlap 1, 3
• Do not administer the Day 1 or Day 8 doses in the gluteal muscle, as this delays achievement of therapeutic concentrations 1, 2

Monitoring During Transition

• Assess clinical response and tolerability at each injection visit 5
• Monitor for extrapyramidal symptoms, weight gain, and metabolic parameters throughout treatment 6
• Evaluate adherence and treatment continuation, as early discontinuation rates are highest in the first few months 5